User:Whatwei/sandbox
| File:Origene wiki logo.jpg | |
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | 1996 |
| Headquarters | |
Key people | |
Number of employees | 300 |
| Website | www.origene.com |
OriGene Technologies, Inc. is an American biotechnology company headquartered in Rockville, Maryland. Its products are used in a variety of life science research and pharmaceutical development. OriGene has the world's largest private collection of full-length human cDNA clones, numbering over 38,000[1].
History
OriGene was founded in 1996 and initially engaged in supplying researchers with northern blot reagents. Since then, OriGene's focus on becoming a 'one-stop shop' for gene-based research products led it to acquiring a variety of companies:
- 2006 - Cytomyx [2]
- 2009 - Marligen Biosciences [3][4]
- 2010 - Blue Heron Biotech LLC [5] [6]
- 2012 - Beijing Zhongshan Golden Bridge Biotechnology [7]
Products
OriGene offers a variety of gene-based research products.
- 38,000 Full-length human cDNA clones [8]
- 7,000 Full-length human proteins [9]
- 3,000 Mouse monoclonal antibodies [10]
Other products include 140,000 [11] tissue products, PCR-related products, Luminex multiplex assays and RNAi products (shRNA, siRNA and miRNA).
Pathology Expansion
In an effort to expand into the pathology field, OriGene recently published a paper on a microarray technology used in testing for antibody specificity [12]. In theory, this technology should ease fears of non-specific binding and reduce the number of false positives when pathologists grade tissues. Antibodies created and screened on this technology have been branded UltraMAB by the company [13].
References
- ^ http://www.origene.com/About/Corporate/
- ^ Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors., Connie L Erickson-Miller, Kodandaram Pillarisetti, Jennifer Kirchner, David J Figueroa, Lone Ottesen, Anne-Marie Martin, Yuan Liu, Yasser Mostafa Kamel, and Conrad Messam, BMC Cancer. 2012; 12: 405.
- ^ http://www.genomeweb.com/rnai/origene-buys-marligen-biosciences
- ^ http://www.bizjournals.com/washington/stories/2009/10/12/daily89.html
- ^ http://www.biospace.com/company_profile.aspx?CompanyId=328504
- ^ http://www.genengnews.com/gen-news-highlights/origene-picks-up-gene-synthesis-firm-blue-heron-biotechnology/81243786/
- ^ http://tickerreport.com/origene-technologies-acquires-beijing-zhongshan-golden-bridge-biotechnology/2810/
- ^ http://www.biosupplynet.com/cfdocs/suppliers/supp_det.cfm?supp_id=8586
- ^ http://gen.epubxp.com/i/83770/77
- ^ http://www.origene.com/assets/documents/Press_releases/3000TrueMAB.pdf
- ^ http://www.jazdlifesciences.com/pharmatech/company/OriGene-Technologies-Inc/TissueFocus.htm?supplierId=30005412&productId=1256895
- ^ http://www.biomedcentral.com/1472-6750/12/88/abstract
- ^ http://www.highbeam.com/doc/1G1-285582069.html